Quanterix Corporation (QTRX) Actualités

Form 8-K - Current report

Quanterix Announces Receipt of Expected Notice from Nasdaq

Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the “Notice”) on November 21, 2024 from The Nasdaq Stock Market...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form 8-K - Current report

Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024

Sixth Consecutive Quarter of Double-Digit Growth Reaffirms Full Year 2024 Outlook Quanterix Corporation (NASDAQ: QTRX), a company fueling...

Quanterix To Report Third Quarter 2024 Financial Results on November 12, 2024

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it...

Form 4 - Statement of changes in beneficial ownership of securities

New Multi-Marker Blood Test from Lucent Diagnostics Increases the Number of Patients Receiving Early Alzheimer’s Disease Diagnostic Information

LucentADTM Complete improves on single biomarker tests, significantly reducing the intermediate zone, providing results for more patients Lucent...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker...